Anixa Biosciences partnering with Cleveland Clinic for breast cancer vaccine
Anixa Biosciences has established a strategic alliance and license agreement with Cleveland Clinic for an innovative breast cancer vaccine technology. Cleveland Clinic researcher Vincent Tuohy has been developing a method to vaccinate women against contracting breast cancer, focused specifically on triple negative breast cancer, the most lethal form of the disease. Tuohy has identified a specific protein that is "retired" from service after a woman has given birth, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein, completely prevents breast cancer in mice. Anixa Biosciences will work with Tuohy and a team at Cleveland Clinic to advance this vaccine to clinical trials in humans to verify the animal studies that demonstrated prevention of breast cancer. Tuohy and Cleveland Clinic were awarded a $6.2M grant from the U.S. Department of Defense in November 2017 to provide funding for the completion of pre-clinical studies as well as the completion of two Phase 1 clinical studies to test the vaccine in patients.